Evidence map›Paper›PMID 38954321›Full record

Observational studyJournal of general internal medicine2024

Assessing Substance Use Disorder Symptoms with a Checklist among Primary Care Patients with Opioid Use Disorder and/or Long-Term Opioid Treatment: An Observational Study.

Emily C Williams, Theresa E Matson, Kevin A Hallgren, Malia Oliver, Xiaoming Wang, Katharine A Bradley

Abstract readObservational Study
In one paragraph

Observational study in Journal of general internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emily C WilliamsDepartment of Health Systems and Population Health, University of Washington School of Public Health, The Hans Rosling Building, Floor 4, Seattle, WA, 98195, USA. emwilli@uw.edu.
Theresa E MatsonDepartment of Health Systems and Population Health, University of Washington School of Public Health, The Hans Rosling Building, Floor 4, Seattle, WA, 98195, USA.
Kevin A HallgrenDepartment of Health Systems and Population Health, University of Washington School of Public Health, The Hans Rosling Building, Floor 4, Seattle, WA, 98195, USA.
Malia OliverKaiser Permanente Washington Health Research Institute, Seattle, WA, 98101, USA.
Xiaoming WangNational Institute On Drug Abuse, Clinical Trials Network, Bethesda, MD, USA.
Katharine A BradleyDepartment of Health Systems and Population Health, University of Washington School of Public Health, The Hans Rosling Building, Floor 4, Seattle, WA, 98195, USA.

Funding

Project-002UG1DA040314 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Ingrid A Binswanger, CYNTHIA I CAMPBELL · 2015 to 2026
$34.9M
National Drug Abuse Treatment Clinical Trials Network UG1DA040314NIDA NIH HHS UG1 DA040314
6 · The paper itself

Abstract

backgroundPrimary care (PC) offers an opportunity to treat opioid use disorders (OUD). The Substance Use Symptom Checklist ("Checklist") can assess DSM-5 substance use disorder (SUD) symptoms in PC.

objectiveTo test the psychometric properties of the Checklist among PC patients with OUD or long-term opioid therapy (LTOT) in Kaiser Permanente Washington (KPWA).

designObservational study using item response theory (IRT) and differential item functioning (DIF) analyses of measurement consistency across age, sex, race and ethnicity, and receipt of treatment. PATIENTS: Electronic health records (EHR) data were extracted for all adult PC patients visiting KPWA 3/1/15-8/30/2020 who had ≥ 1 Checklist documented and indication of either (a) clinically-recognized OUD (i.e., documented OUD diagnosis and/or OUD medication treatment) or (b) LTOT in the year prior to the checklist. MAIN MEASURE: The Checklist includes 11 items reflecting DSM-5 criteria for SUD. We described the prevalence of 2 SUD symptoms reported on the Checklist (consistent with mild-severe DSM-5 SUD). Analyses were conducted in the overall sample and in two subsamples (clinically-recognized OUD and LTOT only). KEY

resultsAmong 2007 eligible patients, 39.9% endorsed ≥ 2 SUD symptoms (74.3% in the clinically-recognized OUD subsample and 13.1% in LTOT subsample). IRT indicated that a unidimensional model for the 11 checklist items had excellent fit (comparative fit index = 0.998) with high item-level discrimination parameters for the overall sample and both subsamples. DIF across age, race and ethnicity, and treatment was observed for one item each, but had minimal impact on expected number of criteria (0-11) patients endorse.

conclusionsThe Substance Use Symptom Checklist measured SUD symptoms consistent with DSM-5 conceptualization (scaled, unidimensional) in patients with clinically-recognized OUD and LTOT and had similar measurement properties across demographic subgroups. The Checklist may support symptom assessment in patients with OUD and diagnosis in patients with LTOT.

Indexed as

ChecklistOpioid-Related DisordersPrimary Health CareAdultAgedAnalgesics, OpioidFemaleHumansMaleMiddle AgedOpiate Substitution TreatmentPsychometricsSubstance-Related DisordersYoung AdultAnalgesics, Opioidopioidsopioid use disordersubstance use disordersymptom assessment

Identifiers

PMID38954321
PMCPMC11347511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.